Puma Biotechnology | PBYI - Cash And Equivalent


Puma Biotechnology reported $53.52M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025